Protez Pharmaceuticals, Inc.
Novel antibiotic candidate (PZ-601) focused on drug resistance in difficult to treat infections. Acquired by Novartis in 2008.
Exited Portfolio Company
Novel antibiotic candidate (PZ-601) focused on drug resistance in difficult to treat infections. Acquired by Novartis in 2008.
Exited Portfolio Company